Drug Target Insights最新文献_第2页

Evaluation of non-conformities in the drafting of bulletins for urine cytobacteriological examinations at Sikasso Hospital (Mali). 评估锡卡索医院（马里）尿液细胞细菌学检查公告起草过程中的不合规之处。

IF 2.7

Drug Target Insights Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.2670

Luka Diarra, Moussa Mariko, Salif Traore, Safi Bazi Dicko, Aboudou Dolo, Moussa Coulibaly, Daouda Sidibé, Moumouni Daou, Hachimi Poma, Madou Traore, Ibrahim Guindo

{"title":"Evaluation of non-conformities in the drafting of bulletins for urine cytobacteriological examinations at Sikasso Hospital (Mali).","authors":"Luka Diarra, Moussa Mariko, Salif Traore, Safi Bazi Dicko, Aboudou Dolo, Moussa Coulibaly, Daouda Sidibé, Moumouni Daou, Hachimi Poma, Madou Traore, Ibrahim Guindo","doi":"10.33393/dti.2024.2670","DOIUrl":"10.33393/dti.2024.2670","url":null,"abstract":"Background: Non-compliance in the drafting of examination bulletins makes it difficult to perform them and interpret the results. With the aim of continuously improving laboratory services and guaranteeing the quality of urine cytobacteriological examination (ECBU) results, we initiated this study to evaluate non-compliance in the drafting of ECBU reports.Materials and methods: This was a retrospective descriptive cross-sectional study which focused on non-compliance in the drafting of ECBU reports analysed in the laboratory from January to December 2022.Results: During the study period, we collected 383 non-compliant ECBU reports out of 672, with a frequency of 56.99%. Non-compliances were related to age (2.68%), profession (24.40%), clinical information (6.70%) and residence (52.08%). The majority of non-compliant reports came from the medicine (35.51%) and urology (25.85%) departments.Conclusion: The high frequency of non-compliance is a cause for concern and is of concern to all prescribers in this hospital.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"1-3"},"PeriodicalIF":2.7,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139490633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of urinary tract infections in the era of antimicrobial resistance. 抗菌药耐药性时代的尿路感染管理。

IF 2.7

Drug Target Insights Pub Date : 2023-12-20 eCollection Date: 2023-01-01 DOI: 10.33393/dti.2023.2660

Ria Pothoven

引用次数: 0

Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection 碳青霉烯耐药肠杆菌科感染的死亡率及其相关因素

Drug Target Insights Pub Date : 2023-10-30 DOI: 10.33393/dti.2023.2622

Apichart So-ngern, Naphol Osaithai, Atibordee Meesing, Worawat Chumpangern

{"title":"Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection","authors":"Apichart So-ngern, Naphol Osaithai, Atibordee Meesing, Worawat Chumpangern","doi":"10.33393/dti.2023.2622","DOIUrl":"https://doi.org/10.33393/dti.2023.2622","url":null,"abstract":"Background: Carbapenem-resistant Enterobacteriaceae (CRE) is a serious pathogen with high mortality. Recognition of factors associated with mortality and treating these modifiable factors are crucial to reducing mortality.Objective: To determine the 30-day mortality and factors associated with a 30-day mortality of CRE infection.Methods: A retrospective cohort study was conducted between January 1, 2015, and December 31, 2019. All patients diagnosed with CRE infection aged ≥18 years were included. Multivariate logistic regression was used for evaluating the factors associated with 30-day mortality and presented as adjusted odds ratio (aOR) with 95% confidence interval (CI).Result: One hundred and ninety-four patients were enrolled. The 30-day mortality occurred in 75 patients (38.7%). The common antibiotic regimen was monotherapy and combination of carbapenem, colistin, amikacin, tigecycline, and fosfomycin. CRE isolates were susceptible to tigecycline (93.8%), colistin (91.8%), fosfomycin (89.2%), and amikacin (89.2%). The independent factors associated with 30-day mortality were an increasing simplified acute physiology (SAP) II score (aOR 1.11, 95% CI 1.05-1.16, p < 0.001), sepsis at time of CRE infection diagnosis (aOR 7.93, 95% CI 2.21-28.51, p = 0.002), pneumonia (aOR 4.48, 95% CI 1.61-12.44, p = 0.004), monotherapy (aOR 4.69, 95% CI 1.71-12.85, p = 0.003), and improper empiric antibiotic (aOR 5.13, 95% CI 1.83-14.40, p = 0.002).Conclusion: The overall 30-day mortality of CRE infection was high. The factors associated with mortality were an increasing SAP II score, sepsis at time of CRE infection diagnosis, pneumonia, monotherapy, and improper empiric antibiotic. The study suggested that proper empiric antibiotic and combination antibiotics might reduce mortality from CRE infection.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"431 ","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136104057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of antibiotic misuse in cases of pneumonia and diarrhea in Saudi Arabia. 沙特阿拉伯肺炎和腹泻患者滥用抗生素的患病率。

IF 2.7

Drug Target Insights Pub Date : 2023-10-09 eCollection Date: 2023-01-01 DOI: 10.33393/dti.2023.2614

Ebtehaj Saud Almughais, Fatmah Fahad Alreshidi, Hussain Gadelkarim Ahmed

{"title":"Prevalence of antibiotic misuse in cases of pneumonia and diarrhea in Saudi Arabia.","authors":"Ebtehaj Saud Almughais, Fatmah Fahad Alreshidi, Hussain Gadelkarim Ahmed","doi":"10.33393/dti.2023.2614","DOIUrl":"10.33393/dti.2023.2614","url":null,"abstract":"Background: Antibiotic misuse is a major public health issue with long-term repercussions.Objective: The purpose of this investigation was to evaluate the effects of pneumonia and diarrhea, with an emphasis on antibiotic misuse.Methodology: This study included 410 participants (217 fathers and 193 mothers), of whom 239 purchased antibiotics for their children without a prescription, whereas 171 had a prescription or were unsure if one was required.Results: Antibiotics were used incorrectly by 58.1% of respondents. About 51.2% of participants said they were taking two antibiotics at the same time. Around 30% of people admitted to using antibiotics inefficiently. The most prevalent reason for use was \"viral and bacterial,\" followed by \"viral,\" and then \"bacterial,\" with 35%, 21%, and 20%, respectively. In addition, 22.4% of patients have used antibiotics for an unknown reason.Conclusion: Saudi parents of children with pneumonia and diarrhea abuse antibiotics. Saudi legislation banning medications without a prescription has helped reduce antibiotic abuse, but more community-based education and awareness are needed.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"114-119"},"PeriodicalIF":2.7,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/1a/dti-17-114.PMC10563503.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression. 一线替波替尼用于一名患有转移性NSCLC的高龄患者，该患者携带MET外显子14跳跃突变和高PD-L1表达。

IF 2.7

Drug Target Insights Pub Date : 2023-10-06 eCollection Date: 2023-01-01 DOI: 10.33393/dti.2023.2626

Alessandro Inno, Giuseppe Bogina, Giulio Settanni, Matteo Salgarello, Giovanni Foti, Carlo Pomari, Vincenzo Picece, Stefania Gori

{"title":"First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression.","authors":"Alessandro Inno, Giuseppe Bogina, Giulio Settanni, Matteo Salgarello, Giovanni Foti, Carlo Pomari, Vincenzo Picece, Stefania Gori","doi":"10.33393/dti.2023.2626","DOIUrl":"10.33393/dti.2023.2626","url":null,"abstract":"Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition gene (MET) exon 14 skipping mutation has not been established yet. MET inhibitors were demonstrated to be effective and tolerated in patients with this condition, while evidence on safety and efficacy of immunotherapy and/or chemotherapy in this population is limited. Here we report the case of an 86-year-old male with metastatic NSCLC harboring MET exon 14 skipping mutation and with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%). The patient received the MET inhibitor tepotinib as first-line treatment, achieving a partial response, with G2 peripheral edema as adverse event that was successfully managed with temporary discontinuation, dose reduction, diuretics and physical therapy. After 31 months, the patient is still receiving tepotinib, with an ongoing response. Tepotinib is a valuable therapeutic option for first-line treatment of older patients with NSCLC harboring MET exon 14 skipping mutation, even in the presence of high PD-L1 expression.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"110-113"},"PeriodicalIF":2.7,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/1e/dti-17-110.PMC10568218.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of anti-pathogenic activity among in silico predicted small-molecule inhibitors of Pseudomonas aeruginosa LasR or nitric oxide reductase (NOR). 在硅预测的铜绿假单胞菌LasR或一氧化氮还原酶（NOR）小分子抑制剂中鉴定抗致病活性。

IF 2.7

Drug Target Insights Pub Date : 2023-09-28 eCollection Date: 2023-01-01 DOI: 10.33393/dti.2023.2638

Gemini Gajera, Niel Henriksen, Bryan Cox, Vijay Kothari

{"title":"Identification of anti-pathogenic activity among in silico predicted small-molecule inhibitors of Pseudomonas aeruginosa LasR or nitric oxide reductase (NOR).","authors":"Gemini Gajera, Niel Henriksen, Bryan Cox, Vijay Kothari","doi":"10.33393/dti.2023.2638","DOIUrl":"10.33393/dti.2023.2638","url":null,"abstract":"Introduction: Antibiotic-resistant Pseudomonas aeruginosa strains cause considerable morbidity and mortality globally. Identification of novel targets in this notorious pathogen is urgently warranted to facilitate discovery of new anti-pathogenic agents against it. This study attempted to identify small-molecule inhibitors of two important proteins LasR and nitric oxide reductase (NOR) in P. aeruginosa. 'Las' system can be said to be the 'master' regulator of quorum sensing in P. aeruginosa, whose receptor protein is LasR. Similarly, NOR is crucial to detoxification of reactive nitrogen species.Methods: In silico identification of potential LasR or NOR inhibitors was attempted through a virtual screening platform AtomNet® to obtain a final subset of <100 top scoring compounds. These compounds were evaluated for their in vivo anti-pathogenic activity by challenging the model host Caenorhabditis elegans with P. aeruginosa in the presence or absence of test compounds. Survival of the worm population in 24-well assay plates was monitored over a period of 5 days microscopically.Results: Of the 96 predicted LasR inhibitors, 11 exhibited anti-Pseudomonas activity (23%-96% inhibition of bacterial virulence as per third-day end-point) at 25-50 µg/mL. Of the 85 predicted NOR inhibitors, 8 exhibited anti-Pseudomonas activity (40%-85% inhibition of bacterial virulence as per second-day end-point) at 25-50 µg/mL.Conclusion: Further investigation on molecular mode of action of compounds found active in this study is warranted. Virtual screening can be said to be a useful tool in narrowing down the list of compounds requiring actual wet-lab screening, saving considerable time and efforts for drug discovery.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"101-109"},"PeriodicalIF":2.7,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/04/dti-17-101.PMC10551673.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41108367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ESBL and carbapenemase-producing Enterobacteriaceae in infectious pleural effusions: current epidemiology at Hôpital du Mali. 感染性胸腔积液中ESBL和产碳青霉烯酶的肠杆菌科：马里医院的当前流行病学。

IF 2.7

Drug Target Insights Pub Date : 2023-08-29 eCollection Date: 2023-01-01 DOI: 10.33393/dti.2023.2613

Aimé Césaire Kalambry, Tchamou Malraux Fleury Potindji, Ibrehima Guindo, Ambara Kassogue, Boubacar Sidiki Ibrahim Drame, Seydou Togo, Sadio Yena, Seydou Doumbia, Mahamadou Diakite

{"title":"ESBL and carbapenemase-producing Enterobacteriaceae in infectious pleural effusions: current epidemiology at Hôpital du Mali.","authors":"Aimé Césaire Kalambry, Tchamou Malraux Fleury Potindji, Ibrehima Guindo, Ambara Kassogue, Boubacar Sidiki Ibrahim Drame, Seydou Togo, Sadio Yena, Seydou Doumbia, Mahamadou Diakite","doi":"10.33393/dti.2023.2613","DOIUrl":"10.33393/dti.2023.2613","url":null,"abstract":"Background: Antimicrobial resistance (AMR) is a global health concern, with extended-spectrum β-lactamases (ESBLs) and carbapenemases being major contributors. Pleural infection (PI) is a severe condition in West Africa, complicated by AMR. This study aimed to investigate the prevalence and molecular characteristics of ESBL and carbapenemase-producing enterobacteria in pleural effusions in Mali.Materials and methods: Pleural fluid samples from 526 patients with pleuritis were analyzed. Enterobacterial species were isolated and identified, and the prevalence of resistance genes (blaOXA-48, blaNDM-1, blaKPC, blaTEM, blaSHV) and virulence factors was determined.Results: Among the patients, 110 were diagnosed with enterobacterial pleuritis. Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis were the main pathogens identified. Resistance to β-lactams and cephalosporins was high, while carbapenems showed good activity. ESBL production was detected in 33.6% of isolates, with blaTEM being the most common gene. Carbapenemase gene (blaNDM-1) was found in three isolates.Conclusion: The study highlights the high prevalence of multidrug-resistant bacteria and the need for appropriate antibiotic selection based on local resistance patterns. Understanding the molecular characteristics of resistance is crucial for optimizing patient care and developing effective therapeutic strategies. Further research is needed to monitor and control AMR in PIs in Mali.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"92-100"},"PeriodicalIF":2.7,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/3b/dti-17-92.PMC10466504.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10152156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of anti-pathogenic activity among in silico predicted small-molecule inhibitors of Pseudomonas aeruginosa LasR or nitric oxide reductase (NOR) 铜绿假单胞菌LasR或一氧化氮还原酶(NOR)的计算机预测小分子抑制剂的抗病原活性鉴定

IF 2.7

Drug Target Insights Pub Date : 2023-07-17 DOI: 10.1101/2023.07.17.549273

G. Gajera, N. Henriksen, Bryan Cox, V. Kothari

{"title":"Identification of anti-pathogenic activity among in silico predicted small-molecule inhibitors of Pseudomonas aeruginosa LasR or nitric oxide reductase (NOR)","authors":"G. Gajera, N. Henriksen, Bryan Cox, V. Kothari","doi":"10.1101/2023.07.17.549273","DOIUrl":"https://doi.org/10.1101/2023.07.17.549273","url":null,"abstract":"Antibiotic resistant Pseudomonas aeruginosa strains cause considerable morbidity and mortality. Identification of novel targets in this notorious pathogen is urgently warranted to facilitate discovery of new anti-pathogenic agents acting against it. Attacking non-essential targets is believed to be a potential anti-virulence strategy. This study attempted to identify small molecule inhibitors of two important proteins LasR and nitric oxide reductase (NOR) in P. aeruginosa. This bacterial pathogen possesses multiple quorum sensing (QS) systems to regulate expression of many of its genes including those associated with virulence. Among these QS systems, ‘Las’ system can be said to be the ‘master’ regulator, whose receptor protein is LasR. Similarly, NOR plays crucial role in detoxification of reactive nitrogen species. This study attempted in silico identification of potential LasR or NOR inhibitors through a virtual screen employing AtomNet®, a proprietary deep learning neural network. Following virtual screening of a large number of compounds for their affinity to LasR or NOR, a final subset of <100 compounds was created by clustering and filtering the top scoring compounds. These compounds were evaluated for their in vivo anti-pathogenic activity by challenging the model host Caenorhabditis elegans with P. aeruginosa in presence or absence of test compounds. Survival of the worm population in 24-well assay plates was monitored over a period of 5 days microscopically. Of the 96 predicted LasR inhibitors, 11 exhibited anti-Pseudomonas activity (23-96% inhibition of bacterial virulence as per third-day end point) at 25-50 µg/ml. Of the 85 predicted NOR inhibitors, 8 exhibited anti-Pseudomonas activity (40-85% inhibition of bacterial virulence as per second-day end point) at 25-50 µg/ml. Further investigation on molecular mode of action of active compounds is warranted.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 1","pages":"101 - 109"},"PeriodicalIF":2.7,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45888013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Licorice as a herbal extract in periodontal therapy. 甘草作为一种草药提取物用于牙周治疗。

IF 2.7

Drug Target Insights Pub Date : 2023-06-05 eCollection Date: 2023-01-01 DOI: 10.33393/dti.2023.2583

Safiya Fatima Khan, Bhavya Shetty, Ibrahim Fazal, Asim Mustafa Khan, Faheem Muzaffar Mir, Muhamood Moothedath, V J Reshma, Muhaseena Muhamood

{"title":"Licorice as a herbal extract in periodontal therapy.","authors":"Safiya Fatima Khan, Bhavya Shetty, Ibrahim Fazal, Asim Mustafa Khan, Faheem Muzaffar Mir, Muhamood Moothedath, V J Reshma, Muhaseena Muhamood","doi":"10.33393/dti.2023.2583","DOIUrl":"10.33393/dti.2023.2583","url":null,"abstract":"Periodontal disease is caused by specific pathogens which results in inflammation of the tooth-supporting structures and subsequently causes the continued breakdown of alveolar bone and periodontal ligament. Licorice (Glycyrrhiza glabra) is a perennial herb with substantial medicinal value. Licorice extract is derived from dried, unpeeled stolons and roots of Glycyrrhiza uralensis and G. glabra. The bioactive ingredients in licorice extract such as glycyrrhizin, licoricidin, glabridin, licochalcone A, and licorisoflavan A have anti-inflammatory, antimicrobial, and anti-adherence effects that are beneficial against periodontal disease. Since periodontal disease has a complex etiology that includes the host response and microorganisms, licorice phytochemicals offer a therapeutic advantage due to their dual functionality. The aim of this review was to enumerate the bioactive compounds present in herbal licorice extract and to elucidate the beneficial effects of licorice and its derivatives in periodontal therapy. Literature review and clinical trials evaluating the effect of licorice on periodontopathogens and periodontal disease are included in this article.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"70-77"},"PeriodicalIF":2.7,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/86/dti-17-70.PMC10243202.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9597793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Licorice as a herbal extract in periodontal therapy 甘草提取物在牙周治疗中的应用

Drug Target Insights Pub Date : 2023-06-05 DOI: 10.33393/dti.2023.2583

Safiya Fatima Khan, Bhavya Shetty, Ibrahim Fazal, Asim Mustafa Khan, Faheem Muzaffar Mir, Muhamood Moothedath, Reshma VJ, Muhaseena Muhamood

{"title":"Licorice as a herbal extract in periodontal therapy","authors":"Safiya Fatima Khan, Bhavya Shetty, Ibrahim Fazal, Asim Mustafa Khan, Faheem Muzaffar Mir, Muhamood Moothedath, Reshma VJ, Muhaseena Muhamood","doi":"10.33393/dti.2023.2583","DOIUrl":"https://doi.org/10.33393/dti.2023.2583","url":null,"abstract":"Periodontal disease is caused by specific pathogens which results in inflammation of the tooth-supporting structures and subsequently causes the continued breakdown of alveolar bone and periodontal ligament. Licorice (Glycyrrhiza glabra) is a perennial herb with substantial medicinal value. Licorice extract is derived from dried, unpeeled stolons and roots of Glycyrrhiza uralensis and G. glabra. The bioactive ingredients in licorice extract such as glycyrrhizin, licoricidin, glabridin, licochalcone A, and licorisoflavan A have anti-inflammatory, antimicrobial, and anti-adherence effects that are beneficial against periodontal disease. Since periodontal disease has a complex etiology that includes the host response and microorganisms, licorice phytochemicals offer a therapeutic advantage due to their dual functionality. The aim of this review was to enumerate the bioactive compounds present in herbal licorice extract and to elucidate the beneficial effects of licorice and its derivatives in periodontal therapy. Literature review and clinical trials evaluating the effect of licorice on periodontopathogens and periodontal disease are included in this article.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135658074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1